Pacira | PCRX - Gross Profit On Sales

Stock Price
21.00
Daily Change
0.64 3.14%
Monthly
-19.23%
Yearly
-19.54%
Q1 Forecast
19.91

Pacira reported $130.92M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Astellas Pharma JPY 456.81B 38.02B Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 16.6B 118M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 148.81M 21.01M Sep/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025
Zoetis USD 1.72B 96M Sep/2025